Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics Ltd is advancing its clinical-stage development of PrimeC, an innovative treatment for neurodegenerative diseases, with the Phase 2b PARADIGM study reporting a statistically significant 29.2% slowing in disease progression at six months, which could bolster its attractiveness for strategic partnerships in North America and Europe. The company's commitment to regulatory progress, particularly toward securing Canadian approval anticipated for 2026, enhances the potential for non-dilutive capital through regional commercial partnerships. Additionally, the favorable safety and tolerability profile of PrimeC, as shown in multiple studies, significantly de-risks the program and supports an expanding therapeutic strategy into Alzheimer’s disease.

Bears say

NeuroSense Therapeutics is experiencing significant financial strain, with indications that cash reserves are dwindling, raising concerns regarding the company's liquidity and operational viability. As a clinical-stage biotechnology firm, the reliance on future capital raises to sustain research and development activities is a notable risk factor, particularly in a sector that typically requires substantial funding before generating revenue. Furthermore, the company's dependence on the success of its lead product candidate, PrimeC, may expose it to heightened volatility and uncertainty, limiting investor confidence.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.